|

R-5780 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Rise Therapeutics LLC1

Indications

  • Basal Cell Cancer1
  • Adenoma1
  • Squamous Cell Cancer1
  • Melanoma1
  • Solid Tumor1

Nashville, Tennessee1 trial

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

Sarah Cannon Research Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.